Tirzepatide Sustains Major Weight Loss When Continued Long-Term
SURMOUNT-MAINTAIN shows stopping tirzepatide reverses weight loss, while continuing it preserves ~22% body weight reduction over 2 years.
Summary
The SURMOUNT-MAINTAIN trial tested whether people with obesity could maintain weight loss after tirzepatide by continuing the drug, reducing the dose, or switching to placebo. After a 60-week open-label weight-loss phase, 378 participants were randomized for an additional 52 weeks. Those continuing at their maximum tolerated dose (MTD) maintained a 21.9% total weight reduction from baseline, while those reducing to 5 mg maintained 16.6%, and those switching to placebo retained only 9.9%. Two-thirds of placebo participants regained enough weight to require rescue therapy. Side effects were mostly mild-to-moderate gastrointestinal events. The findings confirm that obesity requires ongoing pharmacological treatment and that even a reduced dose of tirzepatide offers meaningful weight maintenance compared to discontinuation.
Detailed Summary
Obesity is a chronic disease requiring sustained treatment, yet questions persist about whether weight-loss medications can be stopped or reduced after initial success. SURMOUNT-MAINTAIN addresses this directly by examining what happens after people achieve significant weight loss on tirzepatide.
The phase 3b trial enrolled 441 US adults with obesity (BMI ≥30 or ≥27 with comorbidity) across 20 sites. After a 60-week open-label phase on tirzepatide at maximum tolerated dose (10 or 15 mg weekly), 378 participants were randomized to continue MTD, reduce to 5 mg, or switch to placebo for 52 additional weeks — totaling 112 weeks of follow-up.
Results were striking. Participants continuing at MTD achieved a 21.9% total bodyweight reduction from baseline, versus 16.6% for the 5 mg group and only 9.9% for placebo — both active arms statistically superior to placebo (p<0.0001). Most notably, 67% of placebo participants regained ≥50% of lost weight and required rescue therapy, compared to just 8% in the MTD group and 25% in the 5 mg group.
These findings have significant implications for clinical practice. They reinforce that obesity behaves like other chronic diseases — discontinuing effective therapy leads to relapse. The 5 mg dose emerges as a potentially viable lower-cost or lower-side-effect maintenance option for patients who cannot tolerate or afford higher doses.
Key caveats include the study's US-only, predominantly White sample, its industry funding by Eli Lilly, and the relatively short 52-week maintenance window. The modified treatment-regimen estimand used as the primary analysis also introduces complexity in interpreting true drug effect. Longer-term data beyond 2 years remain needed.
Key Findings
- Continuing tirzepatide at MTD maintained 21.9% total bodyweight reduction at 112 weeks vs 9.9% for placebo.
- 67% of placebo-switched participants regained ≥50% of lost weight, requiring rescue therapy.
- Reducing dose to 5 mg preserved 16.6% weight loss — significantly better than placebo but less than MTD.
- Only 8% of participants continuing MTD required rescue therapy for weight regain.
- Gastrointestinal side effects were the most common adverse events, mostly mild-to-moderate.
Methodology
Phase 3b, multicentre, double-blind, randomised, placebo-controlled trial conducted at 20 US sites over 112 weeks, comprising a 60-week open-label weight-loss period followed by a 52-week double-blind maintenance phase. Participants were randomised 3:3:2 to tirzepatide MTD, tirzepatide 5 mg, or placebo; primary endpoint was percentage bodyweight change from baseline to week 112 using a modified treatment-regimen estimand.
Study Limitations
The trial was conducted exclusively in the USA with a predominantly White cohort, limiting generalizability to diverse populations. Funding and study execution by Eli Lilly introduces potential industry bias. The 52-week maintenance window may be insufficient to assess very long-term durability of weight maintenance or cardiovascular outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: